Carboplatin-pemetrexed in treatment of patients with recurrent/metastatic cancers of the head and neck; superior outcomes in oropharyngeal primaries

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Malhotra, Binu ^a   Emily, Bellile ^a   Nguyen, Nghia Pham Trung ^a   Fung, Vicki Kay ^a   Slack, Matthew ^a   Bilich, Rebecca ^a   Papagerakis, Silvana ^a   Worden, Francis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYANOCOBALAMIN; FOLIC ACID; PEMETREXED;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CAROTID ARTERY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DEHYDRATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INFECTION; LARYNX CANCER; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS RESECTION; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; WART VIRUS;

EID: 84915818459     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00362     Document Type: Article

References (15)

1. Gibson, M.K., et al., Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol, 2005. 23(15): p. 3562-7.
2. Vermorken, J.B., et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 2008. 359(11): p. 1116-27.
3. Schultz, R.M., et al., Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res, 1999. 19(1A): p. 437-43.
4. Shih, C., et al., Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul, 1998. 38: p. 135-52.
5. Hanna, N., et al., Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004. 22(9): p. 1589-97.
6. Scagliotti, G.V., et al., Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008. 26(21): p. 3543-51.
7. Scagliotti, G., et al., The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist, 2009. 14(3): p. 253-63.
8. Paz-Ares, L., et al., Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol, 2012. 13(3): p. 247-55.
9. Gilbert, J., et al., Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer, 2012. 118(4): p. 1007-13.
10. Vermorken, J.B., et al., Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer, 2013. 49(13): p. 2877-83.
11. Argiris, A., et al., Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol, 2011. 29(9): p. 1140-5.
12. Urba, S., et al., Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer, 2012. 118(19): p. 4694-705.
13. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009. 45(2): p. 228-47.
14. Argiris, A., Y. Li, and A. Forastiere, Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer, 2004. 101(10): p. 2222-9.
15. Deeken, J.F., et al., Effect of multimodality treatment on overall survival for patients with metastatic or recurrent HPV-positive head and neck squamous cell carcinoma. Head Neck, 2014.